The effects of angiotensin on the diagnostics and haemodynamics in renal angiography. 1983

J H Göthlin, and J Kråkenes, and S Tvete

In 20 patients referred for renal angiography, series were obtained, 30 s., 3 and 10 min. (control) after administration of 0.5 microgram of angiotensin into the selective arterial catheter. 30 s. after angiotensin there was decreased renal volume, decreased renal blood flow, unchanged arterial diameters but narrower veins. The vascular resistance was increased. The diagnostics in neoplasms and cysts were not improved. Angiotensin administration cannot replace a well performed standard renal angiography.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D008297 Male Males
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D003287 Contrast Media Substances used to allow enhanced visualization of tissues. Radiopaque Media,Contrast Agent,Contrast Agents,Contrast Material,Contrast Materials,Radiocontrast Agent,Radiocontrast Agents,Radiocontrast Media,Agent, Contrast,Agent, Radiocontrast,Agents, Contrast,Agents, Radiocontrast,Material, Contrast,Materials, Contrast,Media, Contrast,Media, Radiocontrast,Media, Radiopaque
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J H Göthlin, and J Kråkenes, and S Tvete
January 1989, Renal physiology and biochemistry,
J H Göthlin, and J Kråkenes, and S Tvete
January 1990, Journal of medical engineering & technology,
J H Göthlin, and J Kråkenes, and S Tvete
October 1996, Journal of hypertension,
J H Göthlin, and J Kråkenes, and S Tvete
April 1994, British journal of clinical pharmacology,
J H Göthlin, and J Kråkenes, and S Tvete
September 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS,
J H Göthlin, and J Kråkenes, and S Tvete
January 1994, Blood pressure. Supplement,
J H Göthlin, and J Kråkenes, and S Tvete
November 1976, European journal of clinical investigation,
J H Göthlin, and J Kråkenes, and S Tvete
September 1998, European journal of clinical pharmacology,
J H Göthlin, and J Kråkenes, and S Tvete
July 1967, The British journal of radiology,
J H Göthlin, and J Kråkenes, and S Tvete
January 1983, Acta medica Scandinavica. Supplementum,
Copied contents to your clipboard!